| P50 | author | Rodrigo Machado-Vieira | Q56856236 |
| | Ioline Henter | Q60962006 |
| P2093 | author name string | Carlos A Zarate | |
| | Giacomo Salvadore | |
| | Jacqueline Baumann | |
| | Cristina Wheeler-Castillo | |
| | David Latov | |
| P2860 | cites work | A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. | Q50278208 |
| | Mifepristone in psychotic depression? | Q81403504 |
| | A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder | Q82274548 |
| | Hippocampal atrophy in recurrent major depression | Q24598190 |
| | Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis | Q24647799 |
| | The pharmacology of putative early-onset antidepressant strategies | Q28185617 |
| | Therapeutic use of sleep deprivation in depression | Q28203470 |
| | The Hamilton Depression Rating Scale: has the gold standard become a lead weight? | Q28295571 |
| | Deep brain stimulation for treatment-resistant depression | Q29616769 |
| | Antidepressant effects of ketamine in depressed patients | Q29617327 |
| | A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression | Q29617914 |
| | Efficacy of intravenous citalopram compared with oral citalopram for severe depression. Safety and efficacy data from a double-blind, double-dummy trial | Q30595714 |
| | Evidence of early onset of antidepressant effect in randomized controlled trials. | Q32068424 |
| | An ideal trial to test differential onset of antidepressant effect | Q32068432 |
| | Possible neurobiological mechanisms underlying faster onset of antidepressant action | Q32068436 |
| | Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly. | Q33169853 |
| | Neuroimaging and genetics of antidepressant response to sleep deprivation: implications for drug development | Q33494682 |
| | New approaches to the treatment of refractory depression. | Q33854941 |
| | Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: antidepressant and hypnotic effects | Q33920531 |
| | Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: a review | Q33921132 |
| | Medication augmentation after the failure of SSRIs for depression. | Q33994373 |
| | Antidepressants in long-term therapy: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors | Q34053648 |
| | Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression | Q34112179 |
| | How long does it take for antidepressant therapies to act? | Q34143597 |
| | Effects of the selective nonpeptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice. | Q34203078 |
| | Does mirtazapine have a more rapid onset than SSRIs? | Q34285608 |
| | Antidepressants and the risk of suicidal behaviors | Q34334805 |
| | Antidepressant drugs and the emergence of suicidal tendencies | Q34361870 |
| | Transcranial magnetic stimulation as a therapeutic tool in psychiatry: what do we know about the neurobiological mechanisms? | Q34385977 |
| | Effects of intrathecal thyrotropin-releasing hormone (protirelin) in refractory depressed patients | Q34419936 |
| | Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder | Q34451408 |
| | Sustained antidepressant effect of sleep deprivation combined with pindolol in bipolar depression. A placebo-controlled trial | Q34502718 |
| | 'One night' sleep deprivation stimulates hippocampal neurogenesis | Q34515004 |
| | Enhancing AMPA to NMDA throughput as a convergent mechanism for antidepressant action | Q34522617 |
| | Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder | Q34547629 |
| | Treatment non-adherence in affective disorders. | Q34592227 |
| | Is combination olanzapine and antidepressant medication associated with a more rapid response trajectory than antidepressant alone? | Q46412607 |
| | Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial | Q46422695 |
| | Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression | Q46474969 |
| | Rapid and sustained antidepressant response with sleep deprivation and chronotherapy in bipolar disorder | Q46475015 |
| | MAOI efficacy and safety in advanced stage treatment-resistant depression--a retrospective study | Q46742870 |
| | Mirtazapine orally disintegrating tablets versus venlafaxine extended release: a double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder | Q46896044 |
| | Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis | Q46900290 |
| | Studies on the inactivation of thyrotropin-releasing hormone (TRH). | Q47685096 |
| | Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors | Q48099473 |
| | Ongoing lithium treatment prevents relapse after total sleep deprivation. | Q48197910 |
| | In vivo evaluation by differential pulse voltammetry of the effect of thyrotropin-releasing hormone (TRH) on dopaminergic and serotoninergic synaptic activity in the striatum and nucleus accumbens of the rat. | Q48424378 |
| | Effects of sleep deprivation on serotonergic neuronal activity in the dorsal raphe nucleus of the freely moving cat. | Q48652041 |
| | Improvement in mental depression with decreased thyrotropin response after administration of thyrotropin-releasing hormone | Q48720684 |
| | Transcranial magnetic stimulation in treatment-resistant depressed patients: a double-blind, placebo-controlled trial | Q48729403 |
| | Lithium sustains the acute antidepressant effects of sleep deprivation: preliminary findings from a controlled study | Q48848216 |
| | Differential time course of antidepressant effects after sleep deprivation, ECT, and carbamazepine: clinical and theoretical implications | Q48972685 |
| | Prolongation of the antidepressant response to partial sleep deprivation by lithium | Q49009500 |
| | Acute effects of ketamine in the holeboard, the elevated-plus maze, and the social interaction test in Wistar rats. | Q51551714 |
| | Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. | Q51773858 |
| | A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. | Q51910035 |
| | A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius. | Q53934176 |
| | Sleep deprivation combined with consecutive sleep phase advance as a fast-acting therapy in depression: an open pilot trial in medicated and unmedicated patients. | Q53969159 |
| | Suicide risk during antidepressant treatment. | Q55041518 |
| | A double-blind double-dummy study of citalopram comparing infusion versus oral administration | Q59389019 |
| | Early Augmentation of Sertraline With Methylphenidate | Q60636322 |
| | Comparison of electroconvulsive therapy with imipramine in endogenous depression: a double blind study | Q60646242 |
| | Treatment of imipramine-resistant recurrent depression, III: Efficacy of monoamine oxidase inhibitors | Q67749567 |
| | Paroxetine in the treatment of depression: a comparison with imipramine and placebo | Q68053359 |
| | The timing, specificity and clinical prediction of tricyclic drug effects in depression | Q68165161 |
| | Protirelin (TRH) in depression | Q68350089 |
| | Three-year outcomes for maintenance therapies in recurrent depression | Q68610334 |
| | Chlorimipramine: A double-blind comparison of intravenous versus oral administration in depressed patients | Q69319293 |
| | Understanding the response lag to tricyclics. I. Application of pulse-loading regimens with intravenous clomipramine | Q69556492 |
| | The functioning and well-being of depressed patients. Results from the Medical Outcomes Study | Q69667941 |
| | Rapid achievement of antidepressant effect with intravenous chlorimipramine | Q70077246 |
| | Identification of true drug response to antidepressants. Use of pattern analysis | Q70366893 |
| | Thyroid-imipramine clinical and chemical interaction: Evidence for a receptor deficit in depression | Q70506830 |
| | Short-lasting behavioural effects of thyrotropin-releasing hormone in depressed women: results of placebo-controlled study | Q70519591 |
| | Recovery from depression after one ECT | Q70578437 |
| | Improvement of depression by REM sleep deprivation. New findings and a theory | Q71153667 |
| | Delayed onset of action of antidepressant drugs? Survey of results of Zurich meta-analyses | Q71341271 |
| | Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice | Q71523387 |
| | Onset and time course of antidepressant action: psychopharmacological implications of a controlled trial of electroconvulsive therapy | Q71539010 |
| | Double-blind trial with oral versus intravenous clomipramine in primary depression | Q71787439 |
| | Chronic depression: response to placebo, imipramine, and phenelzine | Q72273115 |
| | The antidepressant response to tricyclics in major depressives is accelerated with adjunctive use of methylphenidate | Q72433434 |
| | Time course of improvement under antidepressant treatment: a survival-analytical approach | Q72909486 |
| | Age-of-onset or age-cohort changes in the lifetime occurrence of depression? | Q73605236 |
| | Electroconvulsive therapy vs. paroxetine in treatment-resistant depression -- a randomized study | Q73934423 |
| | Intravenous versus oral administration of amitriptyline in patients with major depression | Q74078680 |
| | 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. | Q77801199 |
| | Rapid antidepressant response after nocturnal TRH administration in patients with bipolar type I and bipolar type II major depression | Q80361669 |
| | Is there a delay in the antidepressant effect? A meta-analysis | Q81389466 |
| | Initiation and adaptation: a paradigm for understanding psychotropic drug action | Q34732299 |
| | An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. | Q34881233 |
| | Timing is everything: does the robust upregulation of noradrenergically regulated plasticity genes underlie the rapid antidepressant effects of sleep deprivation? | Q35001283 |
| | Challenges in the treatment of depression with psychotic features | Q35111579 |
| | Intravenous antidepressants: a review | Q35673399 |
| | Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials | Q35692269 |
| | A study into predictors for the speed of response to electroconvulsive therapy | Q35877091 |
| | A review of the efficacy of transcranial magnetic stimulation (TMS) treatment for depression, and current and future strategies to optimize efficacy | Q36247983 |
| | Pindolol augmentation of antidepressant response | Q36395646 |
| | Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder | Q36400018 |
| | Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Application to the NIMH treatment of Depression Collaborative Research Program dataset | Q36767600 |
| | The efficacy of acute electroconvulsive therapy in atypical depression | Q36894999 |
| | CRF receptors as a potential target in the development of novel pharmacotherapies for depression | Q37481959 |
| | Rethinking depression and the actions of antidepressants: uncovering the links between the neural and behavioral elements | Q37593268 |
| | A role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence. | Q37876120 |
| | The biological basis of an antidepressant response to sleep deprivation and relapse: review and hypothesis | Q38137418 |
| | Ketamine blocks a conditioned taste aversion (CTA) in neonatal rats | Q38501958 |
| | The use of psychostimulants in general psychiatry. A reconsideration | Q39461886 |
| | Thyrotropin-Releasing Hormone Selectively Depresses Glutamate Excitation of Cerebral Cortical Neurons | Q40248098 |
| | Phase Advance of the Circadian Sleep-Wake Cycle as an Antidepressant | Q40262935 |
| | Are 2-week trials sufficient to indicate efficacy? | Q40483282 |
| | Current concepts of the classification of affective disorders | Q40799027 |
| | Current advances and trends in the treatment of depression | Q41028584 |
| | Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. | Q41169050 |
| | Use of pattern analysis to identify true drug response. A replication | Q41453243 |
| | Onset of antidepressant activity: reexamining the structure of depression and multiple actions of drugs | Q41484049 |
| | Early onset of therapeutic action in depression and greater efficacy of antidepressant treatments: are they related? | Q41623750 |
| | Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. | Q42672203 |
| | A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression | Q42686183 |
| | Role of neuropeptides and amino acids in controlling secretion of hormones from the anterior pituitary gland in pigs. | Q43071373 |
| | Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated | Q43504398 |
| | MAO inhibition and clinical response in depressed patients treated with phenelzine. | Q43583753 |
| | Pindolol augmentation of selective serotonin reuptake inhibitors: PET evidence that the dose used in clinical trials is too low. | Q43812692 |
| | Acute antidepressant effect following pulse loading with intravenous and oral clomipramine | Q43951583 |
| | Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline | Q44270795 |
| | Sleep deprivation reduces proliferation of cells in the dentate gyrus of the hippocampus in rats | Q44392768 |
| | Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression | Q44418347 |
| | Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression | Q44662293 |
| | Prediction of efficacy of antidepressant by 1-week test therapy in depression | Q44673807 |
| | Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression | Q44709359 |
| | Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial | Q44787835 |
| | Effects of the CRF1 antagonist SSR125543A on aggressive behaviors in hamsters | Q44790146 |
| | Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial | Q45176708 |
| | Transcranial magnetic stimulation accelerates the antidepressant effect of amitriptyline in severe depression: a double-blind placebo-controlled study | Q45225960 |
| | An open label trial of C-1073 (mifepristone) for psychotic major depression | Q46152690 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacology | Q128406 |
| P304 | page(s) | 19-41 | |
| P577 | publication date | 2010-01-06 | |
| P1433 | published in | Pharmaceuticals | Q15750667 |
| P1476 | title | The Timing of Antidepressant Effects: A Comparison of Diverse Pharmacological and Somatic Treatments | |
| P478 | volume | 3 | |